Faculty profile

Jon Dorling

ResearcherPediatricsDalhousie University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Dalhousie University directory, so their courses and email address may be missing. Find their university profile.

Jon Dorling

Researcher

Pediatrics

Health Sciences

Dalhousie University

Halifax, Nova Scotia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
10 publications in the last five years, latest in 2025.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2021.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Echocardiography Extremely Low Gestational Age Patent Ductus Arteriosus Preterm Premature Infant

Latest papers

Milking of the Cut Cord During Stabilization of Infants Born Very Premature: A Randomized Controlled Trial.
The Journal of pediatrics · 2025 · senior author
Association of 24-Hour In-house Neonatologist Coverage with Outcomes of Extremely Preterm Infants.
American journal of perinatology · 2024
Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in extremely preterm infants: a clinical practice guideline incorporating family values and preferences.
Archives of disease in childhood. Fetal and neonatal edition · 2024

All 47 publications

Latest funding

Connecting families to improve parental self-efficacy and parent psychosocial and infant health outcomes in the NICU using an eHealth solution: a stepped wedge cluster randomized controlled trial (The CONNECT study)
CIHR · 2022 · Co-investigator
$921,826
Selective Early Medical Treatment of the Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot Randomized Controlled Trial (the SMART PDA Trial)
CIHR · 2021 · Principal investigator
$104,500
The WHEAT International Trial: WithHolding Enteral feeds Around red cell Transfusion to prevent necrotizing enterocolitis in preterm neonates: an international, multi-centre, randomized controlled trial.
CIHR · 2020 · Nominated PI
$2,135,691

All 5 grants and awards

47 publications.

Milking of the Cut Cord During Stabilization of Infants Born Very Premature: A Randomized Controlled Trial.

El-Naggar W, Mitra S, Abeysekera J, Disher T, Woolcott C, Hatfield T, McMillan D, Dorling J

The Journal of pediatrics2025Senior author

DOI: 10.1016/j.jpeds.2024.114444 PMID: 39722339

Association of 24-Hour In-house Neonatologist Coverage with Outcomes of Extremely Preterm Infants.

Debay A, Shah P, Lodha A, Shivananda S, Redpath S, Seshia M, Dorling J, Lapointe A, Canning R, Strueby L, Beltempo M, Canadian Neonatal Network Investigators

American journal of perinatology2024

DOI: 10.1055/a-1772-4637 PMID: 35170012

Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in extremely preterm infants: a clinical practice guideline incorporating family values and preferences.

Mitra S, Whitehead L, Smith K, Maclean B, Nixon R, Veysey A, Campbell-Yeo M, Kuhle S, Gale C, Soll R, Dorling J, Johnston BC

Archives of disease in childhood. Fetal and neonatal edition2024

DOI: 10.1136/archdischild-2023-325445 PMID: 37419686

Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial protocol (SMART-PDA)

Mitra S, Hébert A, Castaldo M, Disher T, El-Naggar W, Dhillon S, Alhassen Z, Koo J, Katheria AC, Hyderi A

BMJ Open202414 citations

DOI: 10.1136/bmjopen-2024-087998

Evaluation of Health-Related Values and Preferences of Adults Who Were Preterm Infants and Parents of Preterm Infants Concerning Use of Prophylactic Cyclooxygenase Inhibitor Drugs.

Mitra S, Hatfield T, Campbell-Yeo M, Dorling J, Johnston BC

JAMA network open2023

DOI: 10.1001/jamanetworkopen.2023.2273 PMID: 36892840

Timing of neonatal mortality and severe morbidity during the postnatal period: a systematic review.

Dol J, Hughes B, Bonet M, Dorey R, Dorling J, Grant A, Langlois EV, Monaghan J, Ollivier R, Parker R, Roos N, Scott H, Shin HD, Curran J

JBI evidence synthesis2023

DOI: 10.11124/jbies-21-00479 PMID: 36300916

The Impact of Restrictive Family Presence Policies in Response to COVID-19 on Family Integrated Care in the NICU: A Qualitative Study.

McCulloch H, Campbell-Yeo M, Richardson B, Dol J, Hundert A, Dorling J, Whitehead L, MacRae G, Bishop T, Afifi J, Earle R, Rose AE, Foye S, Inglis D, Kim T, Leighton C, Melanson A, Simpson DC, Smit M

HERD2022

DOI: 10.1177/19375867211065178 PMID: 34931565

Timing of maternal mortality and severe morbidity during the postpartum period: a systematic review.

Dol J, Hughes B, Bonet M, Dorey R, Dorling J, Grant A, Langlois EV, Monaghan J, Ollivier R, Parker R, Roos N, Scott H, Shin HD, Curran J

JBI evidence synthesis2022

DOI: 10.11124/jbies-20-00578 PMID: 35916004

Postdischarge Iron Status in Very Preterm Infants Receiving Prophylactic Iron Supplementation after Birth.

Landry C, Dorling J, Kulkarni K, Campbell-Yeo M, Morrison L, Ledwidge J, Vincer M, Ghotra S

The Journal of pediatrics2022

DOI: 10.1016/j.jpeds.2022.04.050 PMID: 35577120

Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in preterm infants: a network meta-analysis.

Mitra S, Gardner CE, MacLellan A, Disher T, Styranko DM, Campbell-Yeo M, Kuhle S, Johnston BC, Dorling J

The Cochrane database of systematic reviews2022Senior author

DOI: 10.1002/14651858.cd013846.pub2 PMID: 35363893

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2021

Subject: Prospective PhD student: Echocardiography Dear Professor Dorling, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Milking of the Cut Cord During Stabilization of Infants Born Very Premature: A Randomized Controlled Trial." (2025), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Selective Early Medical Treatment of the Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot Randomized Controlled Trial (the SMART PDA Trial)" (2021), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Jon Dorling

Research

Latest papers

Latest funding

Milking of the Cut Cord During Stabilization of Infants Born Very Premature: A Randomized Controlled Trial.

Association of 24-Hour In-house Neonatologist Coverage with Outcomes of Extremely Preterm Infants.

Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in extremely preterm infants: a clinical practice guideline incorporating family values and preferences.

Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial protocol (SMART-PDA)

Evaluation of Health-Related Values and Preferences of Adults Who Were Preterm Infants and Parents of Preterm Infants Concerning Use of Prophylactic Cyclooxygenase Inhibitor Drugs.

Timing of neonatal mortality and severe morbidity during the postnatal period: a systematic review.

The Impact of Restrictive Family Presence Policies in Response to COVID-19 on Family Integrated Care in the NICU: A Qualitative Study.

Timing of maternal mortality and severe morbidity during the postpartum period: a systematic review.

Postdischarge Iron Status in Very Preterm Infants Receiving Prophylactic&#xa0;Iron Supplementation after Birth.

Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in preterm infants: a network meta-analysis.

Connecting families to improve parental self-efficacy and parent psychosocial and infant health outcomes in the NICU using an eHealth solution: a stepped wedge cluster randomized controlled trial (The CONNECT study)

Selective Early Medical Treatment of the Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot Randomized Controlled Trial (the SMART PDA Trial)

The WHEAT International Trial: WithHolding Enteral feeds Around red cell Transfusion to prevent necrotizing enterocolitis in preterm neonates: an international, multi-centre, randomized controlled trial.

Relative effectiveness and safety of pharmacotherapeutic agents for treatment of patent ductus arteriosus (PDA) in preterm infants: A National Comparative Effectiveness Research (CER) Project

Respiratory management of extremely preterm neonates: Evidence generation and implementation by comparative effectiveness research (CER) using real world data (RWD) from a practice-based research network (PBRN)

Frequent collaborators

Marsha Campbell-Yeo

Souvik Mitra

Justine Dol

Anie Lapointe

Souvik Mitra

Amish Jain

Janet Curran

Stefan Kuhle

Deepak Louis

Marc Beltempo

Ayman Abou Mehrem

Nadya Ben Fadel

Christy Woolcott

Kyong-Soon Lee

Marc Beltempo

Lori Wozney

Annette Elliott Rose

Abhay Lodha

Stephanie Redpath

Lehana Thabane

Dany Weisz

Eu-gene Ng

Amit Mukerji

Michelle Morais

Patrick McGrath

Postdischarge Iron Status in Very Preterm Infants Receiving Prophylactic Iron Supplementation after Birth.